GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Future Medicine Co Ltd (XKRX:341170) » Definitions » EBIT

Future Medicine Co (XKRX:341170) EBIT : ₩-3,811.51 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Future Medicine Co EBIT?

Future Medicine Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2024 was ₩-3,811.51 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-3,811.51 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Future Medicine Co's annualized ROC % for the quarter that ended in Dec. 2024 was -97.28%. Future Medicine Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -752.72%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Future Medicine Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -22.94%.

Future Medicine Co EBIT Historical Data

The historical data trend for Future Medicine Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Future Medicine Co EBIT Chart

Future Medicine Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8,884.89 -11,446.18 -7,237.93 -5,919.67 -3,811.51

Future Medicine Co Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only -8,884.89 -11,446.18 -7,237.93 -5,919.67 -3,811.51

Competitive Comparison of Future Medicine Co's EBIT

For the Biotechnology subindustry, Future Medicine Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Future Medicine Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Future Medicine Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Future Medicine Co's EV-to-EBIT falls into.


;
;

Future Medicine Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-3,811.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Future Medicine Co  (XKRX:341170) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Future Medicine Co's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-4089.657 * ( 1 - 0% )/( (4634.115 + 3773.8)/ 2 )
=-4089.657/4203.9575
=-97.28 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6445.517 - 427.364 - ( 4897.85 - max(0, 3829.456 - 5213.494+4897.85))
=4634.115

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2174.766 - 472.983 - ( 1418.865 - max(0, 3603.16 - 1531.143+1418.865))
=3773.8

Note: The Operating Income data used here is one times the annual (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Future Medicine Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3811.506/( ( (691.974 + max(-505.48, 0)) + (320.752 + max(-408.671, 0)) )/ 2 )
=-3811.506/( ( 691.974 + 320.752 )/ 2 )
=-3811.506/506.363
=-752.72 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 187.293) - (427.364 + 0 + 265.409)
=-505.48

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 105.413) - (472.983 + 0 + 41.101)
=-408.671

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Future Medicine Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=-3811.506/16616.006
=-22.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Future Medicine Co EBIT Related Terms

Thank you for viewing the detailed overview of Future Medicine Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Future Medicine Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Future Medicine Co Ltd (XKRX:341170) » Definitions » EBIT
Comparable Companies
XKRX:188260 XKRX:344860 XKRX:244460 XKRX:179530 XKRX:950220 XKRX:352770 XKRX:251280 XKRX:065650 XKRX:322970 XKRX:266470 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
54 changup-ro, 616, 2 Techno Valley Enterprise Growth Center, Gyeonggi-do, Siheung-dong, LH Pangyo-je, Seongnam-si, KOR, 13449
Website
http://www.futuremedicine.co.kr
Future Medicine Co Ltd is a drug development company. It engages in the development of new drug candidates for anti-inflammatory/anti-fibrosis of non-alcoholic hepatitis (NASH) drugs, oral glaucoma treatments, and chronic kidney disease treatments, as well as targeted and Immuno cancer drugs.

Future Medicine Co Headlines

No Headlines